Avalyn Nue Galerie de photos et vidéos inédites

Avalyn Pharma outlines inhaled fibrosis push after IPO, with pivotal data ahead

Assessing Avalyn Pharma (AVLN) Valuation As Investors React To Recent Share Price Moves

Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights

Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference

Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for ...

Avalyn to Participate in the Jefferies Global Healthcare Conference

Avalyn Pharma Begins IPO Process For Pulmonary Fibrosis Pipeline

Avalyn Pharma Inc AVLN

Avalyn Announces Pricing of Upsized Initial Public Offering

Avalyn Completes Oversubscribed $100 Million Series D Financing to Further Advance Clinical Development of Novel Inhaled Therapies for Pulmonary Fibrosis

Avalyn: Q1 Earnings Snapshot

Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury

Avalyn Pharma Sets IPO at 16.7 Million Shares Priced at $16-$18 Each

Keyword: avalyn hunter

Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs

Avalyn’s New Twist on Older Lung Disease Drugs Attracts $175M for Clinical Trials

Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer

Avalyn Pharma Surges 44% After $300 Million Upsized IPO

Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Avalyn Pharma Inc

Avalyn Pharma Upsized IPO Priced at Top of Expectations

Avalyn seeks $300m from its IPO

Avalyn Announces Initiation of Phase 1b Clinical Study for AP02, its Novel Inhaled Nintedanib

Avalyn to Participate in Upcoming Investor Conference in April

Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Approach to Developing Novel Inhaled Therapies for Lung Diseases at the 2024 ...

Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials

Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile

Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies

Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis, Including Long-Term Efficacy and Imaging Biomarker Data, at ATS 2024

Avalyn Pharma Made Corporate and Clinical Presentations at ATS 2023 Including Results of Long-Term Treatment of Pulmonary Fibrosis with AP01